LETTER TO THE EDITOR
Dear Editor: Although finasteride was approved only for male pattern baldness 1 , it has been in off-label use on female pattern hair loss (FPHL). A pilot study done on postmenopausal women showed that 1mg of finasteride had no effect on FPHL 2 . Following that report, 2.5 mg or 5 mg of finasteride in FPHL was shown to be effective in several case reports and a few studies 3, 4 . This suggests that finasteride may be effective in FPHL, but its optimal dosage on FPHL needs to be clarified. reported that finasteride at 1 mg/day in a patient with FPHL failed to show slowing hair thinning, increasing growth, or improved appearance. Iorizzo et al. 3 showed some improvement in 62% of patients with finasteride 2.5 mg daily and Yeon et al. 4 also reported daily finasteride 5 mg was effective in FPHL, but Carmina and Lobo. 8 reported the opposite result with the same dosage (5 mg/day). A previous report of finasteride 1.25 mg daily was limited to just four hyperandrogenic FPHL people 9 .
This is the first study of daily finasteride 1.25 mg in normoandrogenic FPHL patients. In addition, most previous studies evaluate the efficacy through photographic Values are presented as number or mean±standard deviation. Patients' GA: patients' global assessment score evaluated by 7-point scale, Physician's GA: physician's global assessment score evaluated by 7-point scale. *Defined from the score -3 to ＋3. -3: greatly decreased, -2, moderately decreased, -1, slight decreased, 0: no change, ＋1: slightly increased, ＋2: moderately increased, ＋3: greatly increased. assessment by patients and investigators 8, 9 , but we used phototrichogram for objective evaluation of efficacy. In this study, patients with FPHL did not show a significant increase in hair growth, but hair density and thickness was minimally increased or constant without further hair loss even though the sample size was small and the duration of treatment was short. Most women with FPHL tend to experience more negative body-image, more social anxiety, and poor self-esteem than control subjects 10 .
Therefore, we thought that subjects reporting 'no change' or 'slight increased' about their condition is meaningful in the treatment of FPHL. Previous studies reported drug-related adverse effect such as headache, depression, nausea, hot flushing, menstrual irregularity, or increased body hair in some patients 2, 4, 6 . However, no one reported drug-related symptoms during this study. From this study, we found out that daily finasteride 1.25 mg medication for 28 weeks in FPHL patients show some measurable efficacy but it doesn't show objective clinical efficacy. Therefore, we suggest that a dose higher than 1.25 mg/day, more number of patients and longer duration of treatment are needed to confirm the effects of this clinical trial in normoandrogenic FPHL.
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